Celon Pharma S.A. at the 23rd Scientific Congress of the Polish Pharmaceutical Society
The event covered a broad scope of issues which are the subject of scientific research in response to challenges faced by the modern pharmaceutical sector. At the congress, Mikołaj Matłoka – Leader of the Neuropsychiatry Research Group at Celon Pharma S.A. – presented issues related to the development of innovative drugs in neuropsychiatric indications. His presentation covered i.a. three projects in this area developed in Celon Pharma’s Research and Development Centre: s-ketamine in treatment of drug-resistant depression, PDE10A inhibitor in treatment of psychotic disorders and in Huntington’s disease, as well as 5-HT6 receptor antagonist in treatment of cognitive disorders.